Mark Yarchoan Discusses Personalized Cancer Vaccines in Melanoma Treatment and Prevention - Oncodaily
Mark Yarchoan, co-founder and CSO of Adventris Pharmaceuticals, published a NEJM editorial accompanying the Phase 3 trial of the personalized cancer vaccine Intismeran in adjuvant melanoma, calling the results vindication for a field long marked by clinical failures. He highlights that the curves separate only after ~6 months — consistent with delayed onset of vaccine-induced immunity — and argues Intismeran succeeded where ICI intensification repeatedly failed, since vaccines stimulate new T cell responses while ICIs invigorate existing ones. For investors, the readout supports the vaccine-plus-ICI combination logic in adjuvant settings and, by extension, the neoantigen-prediction pipelines that underpin personalized constructs. Yarchoan also flags the prevention opportunity: a shared vaccine against 25 recurrent mutational hotspots in KRAS, BRAF, and PIK3CA could in theory target mutations found in more than 70% of colorectal, pancreatic, uterine, and melanoma cases.